Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

pany and is based in S. Mamede do Coronado, Portugal.

It is the partner of choice for many companies, having a strong presence in the Iberian peninsula as well as in over 10 countries in Latin America and in around 20 French or Portuguese speaking African countries.

BIAL is strongly committed to therapeutic innovation investing approximately 20% of its turnover in research and development every year. Key research areas for BIAL are the central nervous system, the cardiovascular system and allergology. BIAL currently has several other innovative programs under development, which the company expects to bring to the market within the next years, thereby strengthening its position throughout Europe.

Further information about BIAL can be found at http://www.bial.com

References:

1. Elger C, Halász P, Moreira J et al. Long-term add-on treatment of partial epilepsy with eslicarbazepine acetate. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

2. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001; 42(Suppl 3):27-30.

3. Halász P, Elger C, Ben-Menachem E et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment to carbamazepine in patients with partial-onset seizures. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

4. Gama H, Elger C, Halász P et al. Time of occurence of adverse events in relation to start of treatment with eslicarbazepine acetate as add-on treatment in patients with partial-onset seizures. Abstract presented at the 28th International Epilepsy Congress, Budapest, Hungary, 28 June 2009 - 2 July 2009.

5. Elger C, French J, Halasz P. et al. Evaluation of Eslicarbazepine Acetate as Add-On T
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ ... ) and NanoBio Corporation today announced an exclusive ... for the over-the-counter (OTC) use of NB-001, a ... the treatment of cold sores. Developed by NanoBio, ... that causes cold sores, herpes labialis . ...
(Date:12/16/2009)... SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged ... breast ultrasound imaging system, announced today that Joe ... Board of Directors. ,, Board Chairman Ken ... to large medical devices companies, including GE OEC ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2International Design Team Selected for Nigerian Hospital 54514 1International Design Team Selected for Nigerian Hospital 54514 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 1Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 2Spain Has The 26apos 3BStress 26apos 3B Factor According to Confused com 54509 3First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2
... Dept. of Defense Continues Study of Copper as ... and Improving Indoor Air Quality, NEW YORK, ... trails determining the,antimicrobial effectiveness of copper, brass and ... announced CDA President Andrew G.,Kireta Sr. Of ...
... Tolerance with No Serious Adverse Reactions, BERKELEY ... GNTA ) released findings from the initial clinical,dosing ... is intended,as a treatment for diseases associated with ... conducted in normal volunteers, has shown good,tolerance with ...
Other Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:12/16/2009)... Retirement Services Division has announced plans to introduce ... 2010. The new platform will include a full ... in a variety of themes. Plan sponsors will ... of creative options to support the theme best ... RetireSmart participant engagement platform will be phased in ...
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
(Date:12/16/2009)... Solutions, a national healthcare staffing agency, is honored to announce ... the company’s Recruiters of the Year in Healthcare Traveler magazine’s ... consecutive year that Chris has received such honors and the ... ... December 16, 2009 -- Medical Solutions, a national healthcare staffing ...
(Date:12/16/2009)... 16 Medizone International, Inc. (OTC Bulletin ... of Directors and the Board of Medizone New ... International Inc. holds a 50% interest, agreed on ... and reconvey to Medizone International all global marketing ... International,s Chairman, Edwin G. Marshall said, "Time has ...
(Date:12/16/2009)... risks , , TUESDAY, Dec. 15 (HealthDay News) -- If ... impact on your life that you just can,t wait to ... that you might want to wait at least six months ... could be even better. , The study found that ... the chances of the baby dying, being born prematurely, having ...
Breaking Medicine News(10 mins):Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3
... ELMWOOD PARK, N.J., July 2 PhytoCeuticals, Inc., ... care,formulations, who is the Fast to invent Stable ... granting IS Clinical from,Innovative Skin Care the right ... Inc. effective July 1, 2008., The IS ...
... 2 FGX International,(Nasdaq: FGXI ), a ... and costume jewelry, today announced that Alec Taylor,Chief ... Chief,Financial Officer will be presenting at the Oppenheimer ... 2008 at The Four Seasons Hotel in,Boston., ...
... recent rises in caesarean section rates, according to a ... , The findings come from an analysis of a ... under Professor Gordon Smith, at the University,s Department of ... than 500,000 entries collected by the Scottish Morbidity Record ...
... be viewed as a safe alternative to smoking, experts say ... (STPs), which include products such as snuff and chew tobacco, ... not as much as smoking does. , So say researchers ... risk of cancer. , Reporting in the July issue of ...
... Study suggests explanation for these practices, health benefits , , ... taken a significant stride forward in understanding how relaxation ... by changing patterns of gene activity that affect how ... seen both in long-term practitioners and in newer recruits, ...
... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced that James ... scheduled to present at the,Collins Stewart Growth Conference ... Hotel in New York City., SuperGen,s presentation ...
Other Medicine News:Health News:Termination of IS Clinical From Distributing PhytoCeuticals Formulas 2Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Smokeless Tobacco Products Do Raise Cancer Risk 2Health News:Meditation, Yoga Might Switch Off Stress Genes 2Health News:Meditation, Yoga Might Switch Off Stress Genes 3Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2
...
... easy-to-operate, semi-automatic urine analyzer that ensures accurate ... lab efficiency by reducing "hands on" operator ... it an ideal fit for work areas ... II Analyzer is designed for continuous sample ...
... are positioned in a burr ... of brain activity. They have ... in several lengths to accommodate ... mm twist drill is suitable ...
... electrodes are extra thin and flexible ... burr hole. The narrow cylindrical connector ... and secure attachment to the patented ... electrode designs, they are available with ...
Medicine Products: